Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis

Inclusion Criteria

- Must understand and voluntarily sign an informed consent form

- Must be age > or = to 18 years to 65 years at the time of singing the informed consent
form.

- Must be able to adhere to the study visit schedule and other protocol requirements

- Must have a history of severe plaque type psoriasis for at least 6 months, and at
least a 15% affected total body surface area (BSA)

- Must meet the following clinical laboratory criteria:

- White Blood Cell Count > or = to 3000/cu mm and < 20,000/cu mm

- Platelet count > or = to 100,000/microliters

- Serum creatinine < or = to 1.5 mg/dl

- Total bilirubin < or = to 2.0 mg/dl

- AST (SGOT) and ALT (SGPT) < or = to 1.5 X ULN

- Must have a psoriatic plaque > or = to 2.5 cm in diameter (for biopsy)

- Must be candidate for photo/systemic therapy (a subject is considered a candidate for
photo/systemic therapy if a clinician judges that the subject requires any systemic
therapy (e.g., ultraviolet light B(UVB), Psoralens and long-wave ultraviolet radiation
(PUVA), cyclosporine, corticosteroids, methotrexate, oral retinoids, mycophenolate
mofetil, thioguanine, hydroxyurea, sirolimus, tacrolimus, azathioprine)to control
psoriasis whether or not that subject has a history of receiving systemic therapy)

- Women of child bearing potential (WCBP) must have a negative urine pregnancy test at
Screening (Visit 1). In addition, sexually active WCBP must agree to use two forms of
adequate forms on contraception throughout the trial.

Exclusion Criteria:

- Any serious medical condition, laboratory abnormality , or psychiatric illness that
would prevent the subject from signing the informed consent form

- Pregnant or lactating females

- Any condition, including the presence of laboratory abnormalities, which places the
subject at unacceptable risk if he/she were to participate in the study or confounds
the ability to interpret data from the study

- Current erythrodermic, guttate, or pustular psoriasis

- Use of medication that is metabolized by the CYP3A4 or CYP2A6 pathways within the 14
days of study medication initiation and/or required use of such medication during
study treatment.

- Drinking or ingesting grapefruits, grapefruit juice or grapefruit containing products
within 14 days of study medication initiation

- Use of topical therapy ( topical steroids, topical vitamin A or D analog preparations,
tacrolimus, pimecrolimus, or anthralin) within 14 days of study medications initiation
(Exception: Non-medicated emollients and tar shampoo will be allowed)

- Use of systemic therapy for psoriasis

- Use or phototherapy within 28 days of study medication initiation

- Use Humira or Remicade within 3 months of study medication initiation

- Use of Enbrel within 56 days of study medication initiation

- Use of Raptiva within 56 days of study medication initiation

- Use of Amevive within 6 months of study medication initiation

- Use of any investigational drug within 30 days of study medication initiation or 5
half lives if known

- History of clinically significant cardiac, endocrinologic, pulmonary, neurologic,
psychiatric, hepatic, renal, hematologic, immunologic insufficiency disease or other
major diseases

- Clinically significant abnormality on 12-lead ECG at screening

- Positive HIV, Hepatitis B or Hepatitis C laboratory result at screening

- History of active tuberculosis within previous 3 years

- Clinically significant abnormality on the chest x-ray at screening or on CXR taken
within 6 months of screening

- History of positive purified protein derivative (PPD) test at screening

- History of malignancy within previous five years

- Evidence of skin conditions at the time of screening visit other than psoriasis that
would interfere with evaluations of the effect of study medication on psoriasis